3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDIV
1
Study Type
Interventional
13
Observational
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Melanoma
12
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
4
Lung Neoplasms
4
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Recurrent Squamous Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Motor Activity
1
Kidney Neoplasms
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Adenocarcinoma
1
Interventions
Surveys and Questionnaires
9
Cystectomy
6
Blood Specimen Collection
5
Neoadjuvant Therapy
4
Cystoscopy
4
Drug Therapy
3
avelumab
2
Urination
2
Urinary Diversion
2
Surgical Procedures, Operative
2
Radiotherapy
2
Pioglitazone
2
Microarray Analysis
2
Methods
2
Magnetic Resonance Spectroscopy
2
Interviews as Topic
2
Immunohistochemistry
2
Defecation
2
Biopsy
2
5-aminolevulinic acid hexyl ester
2
trastuzumab deruxtecan
1
sargramostim
1
pembrolizumab
1
erdafitinib
1
enfortumab vedotin
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
Watchful Waiting
1
Urinary Sediment Analysis
1
Therapeutics
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Urinary Bladder Neoplasms
×
Ipilimumab
×
Clear all
NCT03695835
2020-07-22
NIRPA
Gary Onik MD
Completed
27 enrolled